SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    U.S. Preventive Services Task Force. Guide to clinical preventive services, 2nd ed. Baltimore: Williams & Wilkins, 1996.
  • 2
    National Cancer Institute. Prostate cancer screening state-of-the-art statement. Physician data query [computer data base]. Bethesda: National Cancer Institute, 1996.
  • 3
    Ramsey EW. Early detection of prostate cancer. Recommendations from the Canadian Urological Association. Can J Oncol 1997; 4(Suppl:8) 285.
  • 4
    Rose VL. ACP issues guidelines on the early detection of prostate cancer and screening for prostate cancer. Am Family Phys 1997; 56(6): 167475.
  • 5
    von Eschenback A, Murphy HR, Cunningham M, Lins N. American Cancer Society guidelines for the early detection of prostate cancer: update, June 10, 1997. Cancer 1997; 80(9): 18057.
  • 6
    American Urological Association Executive Committee Report. Early detection of prostate cancer. Baltimore: American Urological Association, 1992.
  • 7
    Gohagan JK, Prorock PC, Kramer BS, Kornet JE. Prostate cancer screening in the prostate, lung, colorectal, ovarian screening trial of the National Cancer Institute. J Urol 1994; 19059.
  • 8
    Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkles WJ, Schroder FH. The European randomized study of screening from prostate cancer. J Urol 1999; 161: 11928.
  • 9
    Koss LG. The Papanicolaou test for cervical cancer detection; a triumph and a tragedy. JAMA 1989; 261(5): 73743.
  • 10
    Schwartz KL, Severson RK, Gurney JG, Montie JE. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area 1973–1994. Cancer 1996; 78: 12606.
  • 11
    Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? Cancer 1998; 82(2): 24951.
  • 12
    Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancer. Part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91(12): 101724.
  • 13
    Feuer EJ, Merrill RM, Hankey BF. Part II: cause of death misclassification and recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91(12): 102532.
  • 14
    Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999; 91(12): 10339.
  • 15
    Percy C, Van Holten V, Muir C. International classification of diseases for oncology, 2nd ed. Geneva: World Health Organization, 1990.
  • 16
    Neter J, Wasseran W. Applied linear statistical models. Homewood: Richard D. Irwin, Inc., 1974.
  • 17
    Ostroff EB, Almario J, Kramer H, Golovsky D. Transrectal needle method for biopsy of the prostate: review of 90 case proceedings; frozen aspiration biopsy of prostate. Br J Urol 1975; 47: 22761.
  • 18
    McGregor B, Tulloch AG, Quinlan MF, Lovegrove F. The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol 1978; 50(3): 17881.
  • 19
    Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17(2): 15963.
  • 20
    Rifkin MD, Kurtz AB, Goldberg BB. Prostate biopsy utilizing transrectal ultrasound guidance: diagnosis of nonpalpable cancers. J Ultrasound Med 1983; 2: 1657.
  • 21
    Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 1983; 4(5): 47385.
  • 22
    Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317(15): 90916.
  • 23
    Ragde H, Aldape HC, Bagley CM Jr. Ultrasound-guided prostate biopsy, biopsy gun superior to aspiration. Urology 1988; 32: 5036.
  • 24
    Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF Jr. The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 1993; 71(Suppl 3): 10318.
  • 25
    Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, Happersett L, et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29(4): 75561.
  • 26
    Weissman RM, Scott WW, Isaacs JT, Coffey DS. Concepts related to prostatic cancer as revealed by a study of the dunning R3327 prostatic adenocarcinoma models. In: WilkinsonDM, editor. Advances in medical oncology research and education, 2nd ed. Clinical cancer, principle sites. New York: Pergamon Press, 1979: 31321.
  • 27
    Isaacs JT. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 117.
  • 28
    Messing EM, Manola JS, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341(24): 17818.
  • 29
    Bolla M, Gonazlez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337(5): 295300.
  • 30
    Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 41924.
  • 31
    O'Brien A, Hibberd M. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer. J Intern Med Res 1990; 18(1): 5768.
  • 32
    Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 1993; 16(6): 499509.
  • 33
    Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr., Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995; 154(2 Pt 1): 4248.
  • 34
    Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate [see discussion]. J Urol 1989; 142(1): 715.
  • 35
    Walsh PC, Lepor H. Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 1983; 4(5): 47385.
  • 36
    Bagshaw MA, Ray GR, Pistenma DA, Castellino RA, Meares EM. External beam radiation therapy of primary carcinoma of the prostate. Cancer 1975; 36(2): 7238.
  • 37
    Sandler HM, McShan DL, Lichter AS. Potential improvement in the results of irradiation for prostate carcinoma using improved dose distribution. Int J Radiat Oncol Biol Phys 1992; 22(2): 3617.
  • 38
    O'Brien A, Hibberd M. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer. J Intern Med Res 1990; 18(Suppl 1): 5768.
  • 39
    Blasko JC, Wallner K, Grimm PD, Ragde H. Prostate specific antigen based disease control following ultrasound guided 125 iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995; 154(3): 10969.
  • 40
    Demers RY, Swanson GM, Weiss LK, Kau TY. Increasing incidence of cancer of the prostate. The experience of black and white men in the Detroit metropolitan area. Arch Intern Med 1994;154: 12116.